Target's 15min chart shows KDJ Death Cross, Bearish Marubozu signal.
ByAinvest
Wednesday, Sep 10, 2025 10:49 am ET2min read
ALNY--
The KDJ Death Cross occurs when the K line of the KDJ indicator crosses below the D line, signaling a potential shift in the stock's momentum towards the downside. This formation follows a broader trend of narrowing Bollinger Bands and KDJ Death Cross formations observed in several other stocks, including ASGN and Cushing NextGen .
Technical analysis provides valuable insights into potential stock price movements, but it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions. As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts.
Positive Outlook: Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [2]. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [2]. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [2]. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [2]. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [2]. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [2]. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [2]. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [2]. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [2]. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [2]. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [2]. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [2]. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [2]. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [2]. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [2]. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [2]. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [2]. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [2]. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [2]. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [2]. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [2]. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [2].
References:
[1] https://www.ainvest.com/news/bank-15min-chart-shows-kdj-death-cross-bearish-marubozu-signals-2509/
[2] https://www.ainvest.com/news/bank-15min-chart-shows-kdj-death-cross-bearish-marubozu-2509-86/
https://www.ainvest.com/news/chart-industries-triggers-kdj-golden-cross-bullish-momentum-builds-marubozu-candle-2508-55/
ASGN--
BAC--
BCS--
BINI--
Based on the 15-minute chart of Target's stock, a KDJ Death Cross and Bearish Marubozu pattern emerged on September 10, 2025, at 10:45. This technical indicator suggests a shift in the momentum of the stock price towards a downward trend, with a potential for further decline in value. The sellers currently dominate the market, and the bearish momentum is expected to persist.
Based on the 15-minute chart of Target's stock, a significant shift in momentum was observed on September 10, 2025, at 10:45. The KDJ Death Cross and Bearish Marubozu pattern triggered a bearish signal, suggesting a potential downward trend in the stock price. This pattern, characterized by a long body with no shadows above or below, indicates strong selling pressure [1].The KDJ Death Cross occurs when the K line of the KDJ indicator crosses below the D line, signaling a potential shift in the stock's momentum towards the downside. This formation follows a broader trend of narrowing Bollinger Bands and KDJ Death Cross formations observed in several other stocks, including ASGN and Cushing NextGen .
Technical analysis provides valuable insights into potential stock price movements, but it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions. As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts.
Positive Outlook: Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [2]. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [2]. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [2]. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [2]. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [2]. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [2]. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [2]. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [2]. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [2]. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [2]. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [2]. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [2]. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [2]. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [2]. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [2]. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [2]. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [2]. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [2]. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [2]. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [2]. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [2]. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [2].
References:
[1] https://www.ainvest.com/news/bank-15min-chart-shows-kdj-death-cross-bearish-marubozu-signals-2509/
[2] https://www.ainvest.com/news/bank-15min-chart-shows-kdj-death-cross-bearish-marubozu-2509-86/
https://www.ainvest.com/news/chart-industries-triggers-kdj-golden-cross-bullish-momentum-builds-marubozu-candle-2508-55/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet